Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms

Annals of Surgery

Volumn 251, Issue 5, 2010, Pages 937-945

  Haab, Brian B ^a   Porter, Andrew ^a   Yue, Tingting ^a   Li, Lin ^b   Scheiman, James ^c   Anderson, Michelle A ^c   Barnes, Dawn ^d   Schmidt, C Max ^e   Feng, Ziding ^b   Simeone, Diane M ^d,f  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Departments of Internal Medicine Nephrology   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e INDIANA UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GLYCAN; LECTIN; MUCIN; MUCIN 1; MUCIN 5AC; PROTEIN MUCIN 16; UNCLASSIFIED DRUG; WHEAT GERM AGGLUTININ;

ADULT; ARTICLE; CYST FLUID; CYSTADENOMA; CYSTIC FIBROSIS; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; MICROARRAY ANALYSIS; PANCREAS PSEUDOCYST; PANCREATIC CYSTIC NEOPLASM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN VARIANT;

BIOPSY, FINE-NEEDLE; CARCINOEMBRYONIC ANTIGEN; CYST FLUID; CYSTADENOCARCINOMA; CYSTADENOMA, MUCINOUS; CYSTADENOMA, SEROUS; GLYCOSYLATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LOGISTIC MODELS; MUCIN 5AC; MUCINS; PANCREATIC NEOPLASMS; PANCREATIC PSEUDOCYST; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77951665680     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181d7738d     Document Type: Article

References (48)

1. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gas-trointest Surg. 2000;4:567-579.
2. Singh M, Maitra A. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology. 2007;7:9-19.
3. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gas-troenterol Hepatol. 2006;4:766-781; quiz 665.
4. Wilentz RE, Albores-Saavedra J, Zahurak M, et al. Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 1999;23:1320-1327.
5. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972.
6. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977-987.
7. Adsay NV. Cystic lesions of the pancreas. Mod Pathol. 2007;20:S71-S93.
8. Winter JM, Cameron JL, Lillemoe KD, et al. Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg. 2006;243:673-680; discussion 680-683.
9. Spinelli KS, Fromwiller TE, Daniel RA, et al. Cystic pancreatic neoplasms: observe or operate. Ann Surg. 2004;239:651-657; discussion 657-659.
10. Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330-1336.
11. van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastroi-ntest Endosc. 2005;62:383-389.
12. Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol. 2005;3:967-973.
13. Raty S, Sand J, Alfthan H, et al. Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions. J Gastroi-ntest Surg. 2004;8:569-574.
14. Shami VM, Sundaram V, Stelow EB, et al. The level of carcinoembryonic antigen and the presence of mucin as predictors of cystic pancreatic mucinous neoplasia. Pancreas. 2007;34:466-469.
15. Hammel PR, Forgue-Lafitte ME, Levy P, et al. Detection of gastric mucins (M1 antigens) in cyst fluid for the diagnosis of cystic lesions of the pancreas. Int J Cancer. 1997;74:286-290.
16. Anderson MA, Kwon RS, Scheiman JM. PANDA cyst fluid analysis: eats, shoots and leaves? Gastrointest Endosc. 2009;69:1103-1105.
17. Burdick MD, Harris A, Reid CJ, et al. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem. 1997;272: 24198-24202.
18. Moniaux N, Andrianifahanana M, Brand RE, et al. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer. 2004;91:1633-1638.
19. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45-60.
20. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta. 1999;1473:21-34.
21. Thompson S, Cantwell BM, Cornell C, et al. Abnormally-fucosylated hapto-globin: a cancer marker for tumour burden but not gross liver metastasis. Br J Cancer. 1991;64:386-390.
22. Okuyama N, Ide Y, Nakano M, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer. 2006;118: 2803-2808.
23. Miyoshi E, Nakano M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics. 2008;8: 3257-3262.
24. Thompson S, Guthrie D, Turner GA. Fucosylated forms of alpha-1-antitryp-sin that predict unresponsiveness to chemotherapy in ovarian cancer. Br J Cancer. 1988;58:589-593.
25. Mita Y, Aoyagi Y, Suda T, et al. Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein. J Hepatol. 2000;32:946-954.
26. Naitoh A, Aoyagi Y, Asakura H. Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14:436-445.
27. Li C, Simeone DM, Brenner DE, et al. Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res. 2009;8:483-492.
28. Zhao J, Patwa TH, Qiu W, et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J Proteome Res. 2007;6: 1864-1874.
29. Chen S, LaRoche T, Hamelinck D, et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods. 2007;4:437-444.
30. Chen S, Haab BB. Antibody microarrays for protein and glycan detection. In: Van Eyk J, Dunn M, eds. Clinical Proteomics. Weinheim, Germany: Wiley, VCH; 2007.
31. Orchekowski R, Hamelinck D, Li L, et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res. 2005;65:11193-11202.
32. Duh MS, Walker AM, Pagano M, et al. Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example. Am J Epidemiol. 1998;147:407-413.
33. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. New York, NY: Springer; 2001.
34. Thall P, Simon R, Grier D. Test-based variable selection via cross-validation. J Comput Graph Stat. 1992;1:41-61.
35. Forrester S, Kuick R, Hung KE, et al. Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer. Mol Oncol. 2007;1:216-225.
36. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med. 1997;75:594-602.
37. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 2006;7:599-604.
38. Schuessler MH, Pintado S, Welt S, et al. Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int J Cancer. 1991;47:180-187.
39. Yu LG. The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J. 2007;24:411-420.
40. Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumors. Immunol Cell Biol. 2005;83:429-439.
41. Saito H, Nishikawa A, Gu J, et al. cDNA cloning and chromosomal mapping of human N-acetylglucosaminyltransferase V +. Biochem Biophys Res Com-mun. 1994;198:318-327.
42. Shimodaira K, Nakayama J, Nakamura N, et al. Carcinoma-associated expression of core 2 beta-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res. 1997;57:5201-5206.
43. McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj J. 1997;14:585-591.
44. Kishimoto T, Ishikura H, Kimura C, et al. Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. Int J Cancer. 1996;69:290-294.
45. Iwai K, Ishikura H, Kaji M, et al. Importance of E-selectin (ELAM-1) and sialyl Lewis (a) in the adhesion of pancreatic carcinoma cells to activated endothelium. Int J Cancer. 1993;54:972-977.
46. Kawarada Y, Ishikura H, Kishimoto T, et al. The role of sialylated Lewis antigens on hematogenous metastases of human pancreas carcinoma cell lines in vivo. Pathol Res Pract. 2000;196:259-263.
47. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897-2902.
48. Takahashi S, Oda T, Hasebe T, et al. Overexpression of sialyl Lewis x antigen is associated with formation of extratumoral venous invasion and predicts postoperative development of massive hepatic metastasis in cases with pancreatic ductal adenocarcinoma. Pathobiology. 2001;69:127-135.